We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Retain PHG Stock in Your Portfolio for Now
Read MoreHide Full Article
Key Takeaways
Philips' equipment order intake rose 8%, while Diagnosis & Treatment orders surged nearly 20%.
Personal Health sales grew 8%, prompting Philips to raise its full-year growth outlook.
EMaaS revenue nearly doubled, but ultrasound delays, China pricing pressure and inflation pose risks.
Koninklijke Philips (PHG - Free Report) is well-positioned for growth on the back of strong order momentum and rising adoption of its differentiated imaging, image-guided therapy and monitoring platforms. Innovation across Spectral CT, helium-free MR and Personal Health products, coupled with market share gains and productivity improvements, should support top- and bottom-line growth. Expanding Monitoring as a Service revenue and a recovering Diagnosis & Treatment order book also offer encouraging prospects.
However, ultrasound manufacturing delays and pricing pressure from China's centralized procurement remain concerns. Persistent inflation, potential tariffs and unresolved Respironics-related proceedings could weigh on profitability and the company's growth trajectory.
Shares of this Zacks Rank #3 (Hold) company have gained 12% in the year-to-date period against the industry’s 15% decline. The S&P 500 Index rose 9.5% in the same time period.
Image Source: Zacks Investment Research
Koninklijke Philips, operating in more than 70 countries, offers solutions in diagnostic imaging, image-guided therapy, patient monitoring, consumer health and home care has a market capitalization of $29.82 billion. The company projects 2.7% earnings growth over the next five years.
The company’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 26.44%.
Factors Favoring PHG Stock
Strong Equipment Order Intake and Market-Share Gains: Philips' equipment order intake increased 8% in the third quarter, marking another strong quarter on top of 8% growth in the prior-year period. Diagnosis & Treatment (D&T) was particularly encouraging, with order intake rising nearly 20%, supported by double-digit growth in both Image-Guided Therapy and Precision Diagnosis. The company also secured vendor-of-choice positions at major U.S. health systems, displacing established competitors. Meanwhile, Precision Diagnosis' order book expanded for the third consecutive quarter, indicating improving demand for its imaging portfolio. The stronger order pipeline provides better sales visibility and could support an acceleration in D&T revenue through 2027.
Personal Health Delivers Broad-Based Growth: Personal Health remains an important growth engine for Philips, with comparable sales increasing 8% in the third quarter, building on double-digit growth in the prior-year quarter. Growth was broad-based across businesses and regions, supported by premium shavers, OneBlade, Sonicare and Avent. The company's focus on premiumization, product innovation and stronger retail execution is translating into increased shelf space, distribution expansion and market share gains. Management also highlighted robust sellout trends across its businesses, prompting it to raise its full-year Personal Health growth outlook to the lower end of the high-single-digit range. Sustained execution could help Philips offset slower growth in parts of its healthcare systems business.
Monitoring-as-a-Service Gains Traction: Philips' Connected Care business is benefiting from the increasing adoption of its enterprise monitoring solutions. Monitoring delivered mid-single-digit comparable sales growth in the third quarter, supported by demand for IntelliVue hospital monitors and consumables. More importantly, Enterprise Monitoring as a Service (EMaaS) revenue nearly doubled year over year, demonstrating progress in expanding long-term, service-based relationships with hospitals. These arrangements combine hardware, software and surveillance solutions, potentially deepening customer relationships and increasing recurring revenue visibility. The company's ability to secure large enterprise agreements, including a 24-hospital deployment with Avera Health, could support sustained growth and improve the revenue mix over time.
Challenges for PHG Stock
Ultrasound Manufacturing Disruptions Continue: Philips' D&T performance remains constrained by manufacturing-related delays in ultrasound, which weighed more heavily on Precision Diagnosis sales during the third quarter. Shipment delays associated with manufacturing process improvements extended the expected revenue recovery beyond the company's earlier timeline. Management indicated that production began ramping up only in late third quarter, with affected sales expected to materialize in the fourth quarter and early 2027. This timing mismatch between demand and shipment execution is limiting near-term revenue conversion despite strong order intake. Although the delayed sales could provide a recovery opportunity, further production setbacks would risk postponing the anticipated acceleration in D&T growth.
China's Centralized Procurement Could Intensify Pressure: China remains a significant headwind for Philips' healthcare systems businesses as centralized procurement expands across the market. Management acknowledged that wider implementation of centralized purchasing is likely to increase pricing pressure, potentially affecting both revenue growth and profitability. Although third-quarter order intake in China improved, partly reflecting renewal-program timing and a weaker comparison, Philips remains cautious about the sustainability of this momentum. The company expects full-year China sales to remain broadly stable, with Personal Health growth offsetting declines in healthcare systems. Consequently, weaker pricing and demand conditions in China could constrain the group's overall growth, particularly in imaging and other hospital-focused businesses.
Inflation, Tariff Uncertainty and Component Constraints: Philips continues to face cost and supply-chain challenges that could complicate its margin-expansion trajectory. Management expects inflation to have a high-double-digit-million-euro impact at the group level in 2026, with input-cost pressures increasing slightly during the third quarter. The company is also preparing for potential additional U.S. medtech tariffs, although the timing and implications of the ongoing Section 232 investigation remain uncertain. Meanwhile, rising demand for electronic components, including from AI infrastructure, could create supply constraints and require additional sourcing and inventory measures. Although productivity initiatives and supply-chain diversification provide mitigation, these pressures could make the company's medium-term profitability targets more difficult to achieve.
Koninklijke Philips is witnessing a positive estimate revision trend for 2026. In the past 30 days, the Zacks Consensus Estimate for earnings has improved 2 cents to $1.76 per share.
The Zacks Consensus Estimate for fourth-quarter 2026 EPS is pegged at 61 cents, suggesting a decline of 12.9% from the year-ago reported numbers.
Stocks to Consider
Some better-ranked stocks from the broader medical space are Glaukos (GKOS - Free Report) , Intuitive Surgical (ISRG - Free Report) and West Pharmaceutical Services (WST - Free Report) .
Glaukos, currently flaunting a Zacks Rank #1 (Strong Buy), reported third-quarter 2026 adjusted earnings per share (EPS) of 47 cents, which surpassed the Zacks Consensus Estimate by 491.7%. Revenues of $211 million beat the Zacks Consensus Estimate by 25%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GKOS has an estimated earnings growth rate of 155.6% for 2026. The company’s earnings beat estimates in three of the trailing four quarters and missed once, the average surprise being 138.6%.
Intuitive Surgical, currently carrying a Zacks Rank #2 (Buy), reported third-quarter 2026 adjusted EPS of $3.00, which beat the Zacks Consensus Estimate by 13.6%. Revenues of $3.05 billion surpassed the Zacks Consensus Estimate by 4.9%.
Intuitive Surgical has a long-term estimated growth rate of 15.5%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 15.1%.
West Pharmaceutical, currently carrying a Zacks Rank #2, reported a third-quarter 2026 adjusted EPS of $2.66, which surpassed the Zacks Consensus Estimate by 22%. Revenues of $874.5 million beat the Zacks Consensus Estimate by 5.9%.
WST has an estimated long-term earnings growth rate of 17.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 18.6%.
Image: Bigstock
Here's Why You Should Retain PHG Stock in Your Portfolio for Now
Key Takeaways
Koninklijke Philips (PHG - Free Report) is well-positioned for growth on the back of strong order momentum and rising adoption of its differentiated imaging, image-guided therapy and monitoring platforms. Innovation across Spectral CT, helium-free MR and Personal Health products, coupled with market share gains and productivity improvements, should support top- and bottom-line growth. Expanding Monitoring as a Service revenue and a recovering Diagnosis & Treatment order book also offer encouraging prospects.
However, ultrasound manufacturing delays and pricing pressure from China's centralized procurement remain concerns. Persistent inflation, potential tariffs and unresolved Respironics-related proceedings could weigh on profitability and the company's growth trajectory.
Shares of this Zacks Rank #3 (Hold) company have gained 12% in the year-to-date period against the industry’s 15% decline. The S&P 500 Index rose 9.5% in the same time period.
Image Source: Zacks Investment Research
Koninklijke Philips, operating in more than 70 countries, offers solutions in diagnostic imaging, image-guided therapy, patient monitoring, consumer health and home care has a market capitalization of $29.82 billion. The company projects 2.7% earnings growth over the next five years.
The company’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 26.44%.
Factors Favoring PHG Stock
Strong Equipment Order Intake and Market-Share Gains: Philips' equipment order intake increased 8% in the third quarter, marking another strong quarter on top of 8% growth in the prior-year period. Diagnosis & Treatment (D&T) was particularly encouraging, with order intake rising nearly 20%, supported by double-digit growth in both Image-Guided Therapy and Precision Diagnosis. The company also secured vendor-of-choice positions at major U.S. health systems, displacing established competitors. Meanwhile, Precision Diagnosis' order book expanded for the third consecutive quarter, indicating improving demand for its imaging portfolio. The stronger order pipeline provides better sales visibility and could support an acceleration in D&T revenue through 2027.
Personal Health Delivers Broad-Based Growth: Personal Health remains an important growth engine for Philips, with comparable sales increasing 8% in the third quarter, building on double-digit growth in the prior-year quarter. Growth was broad-based across businesses and regions, supported by premium shavers, OneBlade, Sonicare and Avent. The company's focus on premiumization, product innovation and stronger retail execution is translating into increased shelf space, distribution expansion and market share gains. Management also highlighted robust sellout trends across its businesses, prompting it to raise its full-year Personal Health growth outlook to the lower end of the high-single-digit range. Sustained execution could help Philips offset slower growth in parts of its healthcare systems business.
Monitoring-as-a-Service Gains Traction: Philips' Connected Care business is benefiting from the increasing adoption of its enterprise monitoring solutions. Monitoring delivered mid-single-digit comparable sales growth in the third quarter, supported by demand for IntelliVue hospital monitors and consumables. More importantly, Enterprise Monitoring as a Service (EMaaS) revenue nearly doubled year over year, demonstrating progress in expanding long-term, service-based relationships with hospitals. These arrangements combine hardware, software and surveillance solutions, potentially deepening customer relationships and increasing recurring revenue visibility. The company's ability to secure large enterprise agreements, including a 24-hospital deployment with Avera Health, could support sustained growth and improve the revenue mix over time.
Challenges for PHG Stock
Ultrasound Manufacturing Disruptions Continue: Philips' D&T performance remains constrained by manufacturing-related delays in ultrasound, which weighed more heavily on Precision Diagnosis sales during the third quarter. Shipment delays associated with manufacturing process improvements extended the expected revenue recovery beyond the company's earlier timeline. Management indicated that production began ramping up only in late third quarter, with affected sales expected to materialize in the fourth quarter and early 2027. This timing mismatch between demand and shipment execution is limiting near-term revenue conversion despite strong order intake. Although the delayed sales could provide a recovery opportunity, further production setbacks would risk postponing the anticipated acceleration in D&T growth.
China's Centralized Procurement Could Intensify Pressure: China remains a significant headwind for Philips' healthcare systems businesses as centralized procurement expands across the market. Management acknowledged that wider implementation of centralized purchasing is likely to increase pricing pressure, potentially affecting both revenue growth and profitability. Although third-quarter order intake in China improved, partly reflecting renewal-program timing and a weaker comparison, Philips remains cautious about the sustainability of this momentum. The company expects full-year China sales to remain broadly stable, with Personal Health growth offsetting declines in healthcare systems. Consequently, weaker pricing and demand conditions in China could constrain the group's overall growth, particularly in imaging and other hospital-focused businesses.
Inflation, Tariff Uncertainty and Component Constraints: Philips continues to face cost and supply-chain challenges that could complicate its margin-expansion trajectory. Management expects inflation to have a high-double-digit-million-euro impact at the group level in 2026, with input-cost pressures increasing slightly during the third quarter. The company is also preparing for potential additional U.S. medtech tariffs, although the timing and implications of the ongoing Section 232 investigation remain uncertain. Meanwhile, rising demand for electronic components, including from AI infrastructure, could create supply constraints and require additional sourcing and inventory measures. Although productivity initiatives and supply-chain diversification provide mitigation, these pressures could make the company's medium-term profitability targets more difficult to achieve.
Koninklijke Philips N.V. Price and Consensus
Koninklijke Philips N.V. price-consensus-chart | Koninklijke Philips N.V. Quote
Estimate Trend
Koninklijke Philips is witnessing a positive estimate revision trend for 2026. In the past 30 days, the Zacks Consensus Estimate for earnings has improved 2 cents to $1.76 per share.
The Zacks Consensus Estimate for fourth-quarter 2026 EPS is pegged at 61 cents, suggesting a decline of 12.9% from the year-ago reported numbers.
Stocks to Consider
Some better-ranked stocks from the broader medical space are Glaukos (GKOS - Free Report) , Intuitive Surgical (ISRG - Free Report) and West Pharmaceutical Services (WST - Free Report) .
Glaukos, currently flaunting a Zacks Rank #1 (Strong Buy), reported third-quarter 2026 adjusted earnings per share (EPS) of 47 cents, which surpassed the Zacks Consensus Estimate by 491.7%. Revenues of $211 million beat the Zacks Consensus Estimate by 25%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GKOS has an estimated earnings growth rate of 155.6% for 2026. The company’s earnings beat estimates in three of the trailing four quarters and missed once, the average surprise being 138.6%.
Intuitive Surgical, currently carrying a Zacks Rank #2 (Buy), reported third-quarter 2026 adjusted EPS of $3.00, which beat the Zacks Consensus Estimate by 13.6%. Revenues of $3.05 billion surpassed the Zacks Consensus Estimate by 4.9%.
Intuitive Surgical has a long-term estimated growth rate of 15.5%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 15.1%.
West Pharmaceutical, currently carrying a Zacks Rank #2, reported a third-quarter 2026 adjusted EPS of $2.66, which surpassed the Zacks Consensus Estimate by 22%. Revenues of $874.5 million beat the Zacks Consensus Estimate by 5.9%.
WST has an estimated long-term earnings growth rate of 17.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 18.6%.